Millipore Sigma Vibrant Logo
Attention: We have moved. Merck Millipore products are no longer available for purchase on MerckMillipore.com.Learn More

AB755P Anti-Rat Collagen Type I Antibody

AB755P
100 µg  
Purchase on Sigma-Aldrich

Special Offers

Overview

Replacement Information

Key Spec Table

Species ReactivityKey ApplicationsHostFormatAntibody Type
RELISA, ICC, IH(P), RIARbAffinity PurifiedPolyclonal Antibody
Description
Catalogue NumberAB755P
Brand Family Chemicon®
Trade Name
  • Chemicon
DescriptionAnti-Rat Collagen Type I Antibody
OverviewCollagen Type I extracted and purified from rat skin. Antibody shows less than 0.1% reactivity with human, mouse, chicken Collagen Type I, rat Collagen Types II, III and V and rat Elastin.
Background InformationCollagens are highly conserved throughout evolution and are characterised by an uninterrupted "Glycine X Y" triplet repeat that is a necessary part of the triple helical structure. Type I collagen (95 kDa) is found in bone, cornea, skin and tendon. Mutations in the encoding gene are associated with osteogenesis imperfecta, Ehlers Danlos syndrome, and idiopathic osteoporosis. Reciprocal translocations between chromosomes 17 and 22, where this gene and the gene for Platelet-derived growth factor beta are located, are associated with a particular type of skin tumor called dermatofibrosarcoma protuberans, resulting from unregulated expression of the growth factor.
References
Product Information
FormatAffinity Purified
Control
  • Rat hepatic stellate cell lysate
PresentationThe purified antibody is supplied in a buffer containing a mixture of 0.1M Citrate, 0.1M potassium phosphate, at a pH of 7.2-7.4 and 10µl/ml of antibiotics and antimycotics
Quality LevelMQ100
Applications
ApplicationAnti-Rat Collagen Type I Antibody is an antibody against Collagen Type I for use in ELISA, IC, IH(P), RIA.
Key Applications
  • ELISA
  • Immunocytochemistry
  • Immunohistochemistry (Paraffin)
  • Radioimmunoassay
Applications Not Recommended
  • Western Blotting
Application NotesELISA:
A 1:200 dilution of a previous lot was used in ELISA.

RIA:
A previous lot of this antibody was used in RIA.

Immunocytochemistry:
A 1:40-1:80 dilution of a previous lot was used for immunofluorescent staining of frozen rat skin and liver tissues.
Can also be used for acetone-fixed cells.

Immunohistochemistry:
1:40-1:80 dilution for immunofluorescent staining of frozen rat skin and liver tissues. The antibody is also reactive on paraffin embedded rat tissues (skin, liver) at a tdilution of 1:500 using an ABC detection system.

Not recommended for Western blots.
Optimal working dilutions must be determined by the end user.
Biological Information
ImmunogenCollagen Type I extracted and purified from rat skin.
ConcentrationPlease refer to the Certificate of Analysis for the lot-specific concentration.
HostRabbit
SpecificityRecognizes Rat Collagen Type I
IsotypeIgG
Species Reactivity
  • Rat
Species Reactivity NoteThe antibody shows less than 0.1% reactivity with human, mouse, chicken Collagen Type I, rat Collagen Types II, III and V and rat Elastin.
Antibody TypePolyclonal Antibody
Entrez Gene Number
Entrez Gene SummaryThis gene encodes the pro-alpha1 chains of type I collagen whose triple helix comprises two alpha1 chains and one alpha2 chain. Type I is a fibril-forming collagen found in most connective tissues and is abundant in bone, cornea, dermis and tendon. Mutations in this gene are associated with osteogenesis imperfecta types I-IV, Ehlers-Danlos syndrome type VIIA, Ehlers-Danlos syndrome Classical type, Caffey Disease and idiopathic osteoporosis. Reciprocal translocations between chromosomes 17 and 22, where this gene and the gene for platelet-derived growth factor beta are located, are associated with a particular type of skin tumor called dermatofibrosarcoma protuberans, resulting from unregulated expression of the growth factor. Two transcripts, resulting from the use of alternate polyadenylation signals, have been identified for this gene. [provided by R. Dalgleish]
Gene Symbol
  • COL1A1
  • OI4
Purification MethodImmunoAffinity Purified
UniProt Number
UniProt SummaryFUNCTION: SwissProt: P02452 # Type I collagen is a member of group I collagen (fibrillar forming collagen).
SIZE: 1464 amino acids; 138911 Da
SUBUNIT: Trimers of one alpha 2(I) and two alpha 1(I) chains. Interacts with MRC2 (By similarity).
SUBCELLULAR LOCATION: Secreted, extracellular space, extracellular matrix (By similarity).
TISSUE SPECIFICITY: Forms the fibrils of tendon, ligaments and bones. In bones the fibrils are mineralized with calcium hydroxyapatite.
PTM: Proline residues at the third position of the tripeptide repeating unit (G-X-Y) are hydroxylated in some or all of the chains. & O-linked glycan consists of a Glc-Gal disaccharide bound to the oxygen atom of a post-translationally added hydroxyl group.
DISEASE: SwissProt: P02452 # Defects in COL1A1 are the cause of Caffey disease [MIM:114000]; also known as infantile cortical hyperostosis. Caffey disease is characterized by an infantile episode of massive subperiosteal new bone formation that typically involves the diaphyses of the long bones, mandible, and clavicles. The involved bones may also appear inflamed, with painful swelling and systemic fever often accompanying the illness. The bone changes usually begin before 5 months of age and resolve before 2 years of age. & Defects in COL1A1 are a cause of Ehlers-Danlos syndrome type I (EDS-I) [MIM:130000]; also known as Ehlers-Danlos syndrome gravis. Ehlers-Danlos syndrome is a genetically and phenotypically heterogeneous connective-tissue disorder characterized by loose- jointedness and fragile, velvety, stretchable, bruisable skin that heals with peculiar 'cigarette-paper' scars. EDS-I is an autosomal dominant trait. & Defects in COL1A1 are a cause of autosomal dominant Ehlers-Danlos syndrome type VII (EDS-VII) [MIM:130060]; which includes also Ehlers-Danlos syndrome type VII-A1. EDS-VII is characterized by arthrochalasis multiplex congenita, skin hyperextensibility and bruisability. & Defects in COL1A1 are a cause of osteogenesis imperfecta type I (OI-I) [MIM:166200]. OI-I is a dominantly inherited serious newborn disease characterized by bone fragility, normal stature, little or no deformity, blue sclerae and hearing loss in 50% of families. Dentinogenesis imperfecta is rare and may distinguish a subset of OI type I (formation of dentine). & Defects in COL1A1 are a cause of osteogenesis imperfecta type II (OI-II) [MIM:166210]; also known as osteogenesis imperfecta congenita. OI-II is lethal in the perinatal period and is charaterized by calvarial mineralization, beaded ribs, compressed femurs, marked long bone deformity and platyspondyly (congenital flattening of the vertebral bodies). & Defects in COL1A1 are a cause of osteogenesis imperfecta type III (OI-III) [MIM:259420]; also called progressively deforming osteogenesis imperfecta with normal sclerae. OI-III is characterized by progressively deforming bones, usually with moderate deformity at birth, sclerae is variable in color, dentinogenesis imperfecta and hearing loss are common. The stature is very short. & Defects in COL1A1 are a cause of osteogenesis imperfecta type IV (OI-IV) [MIM:166220]. OI-IV is charaterized by normal sclerae, moderate to mild deformity and variable short stature. Dentinogenesis imperfecta is common and hearing loss occurs in some patients. & Genetic variations in COL1A1 are associated with susceptibility to involutional osteoporosis [MIM:166710]; also known as senile osteoporosis or postmenopausal osteoporosis. Osteoporosis is characterized by reduced bone mineral density, disrutption of bone microarchitecture, and the alteration of the amount and variety of non-collagenous proteins in bone. Osteoporotic bones are more at risk of fracture. & A chromosomal aberration involving COL1A1 is a cause of dermatofibrosarcoma protuberans (DFSP) [MIM:607907]. Translocation t(17;22)(q22;q13) with PDGF. DFSP is an uncommon, locally aggressive, but rarely metastasizing tumor of the deep dermis and subcutaneous tissue. It typically occurs during early or middle adult life and is most frequently located on the trunk and proximal extremities.
SIMILARITY: SwissProt: P02452 ## Belongs to the fibrillar collagen family. & Contains 1 VWFC domain
Physicochemical Information
Dimensions
Materials Information
Toxicological Information
Safety Information according to GHS
Safety Information
Product Usage Statements
Quality AssuranceImmunohistochemistry(paraffin):
Collagen Type I (cat. # AB755P) staining pattern/morphology in rat skin. Tissue is pre-treated with Citrate pH 6.0, antigen retrieval. This lot of antibody is diluted to 1:1000, using IHC-Select® reagents used with HRP-DAB. Immunoreactivity is seen fiber-staining on paraffin section. Note that the staining pattern is as expected.

IHC-Paraffin Staining With Epitope Retrieval: Rat Skin
Usage Statement
  • Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Storage and Shipping Information
Storage ConditionsStable for 1 year at -20ºC from date of receipt.
Packaging Information
Material Size100 µg
Transport Information
Supplemental Information
Specifications
Global Trade Item Number
Catalogue Number GTIN
AB755P 04053252339028

Documentation

Anti-Rat Collagen Type I Antibody SDS

Title

Safety Data Sheet (SDS) 

Anti-Rat Collagen Type I Antibody Certificates of Analysis

TitleLot Number
Anti-Rat Collagen Type I - 2446738 2446738
Anti-Rat Collagen Type I - 1986132 1986132
Anti-Rat Collagen Type I - 2208759 2208759
Anti-Rat Collagen Type I - 3243499 3243499
Anti-Rat Collagen Type I - 3510285 3510285
Anti-Rat Collagen Type I - 3787682 3787682
Anti-Rat Collagen Type I - 3905496 3905496
Anti-Rat Collagen Type I - 4040829 4040829
Anti-Rat Collagen Type I - 4157263 4157263
Anti-Rat Collagen Type I - JC1618207 JC1618207

References

Reference overviewApplicationSpeciesPub Med ID
An Autologous Muscle Tissue Expansion Approach for the Treatment of Volumetric Muscle Loss.
Ward, CL; Ji, L; Corona, BT
BioResearch open access  4  198-208  2015

Show Abstract
26309796 26309796
Heterogeneity in arterial remodeling among sublines of spontaneously hypertensive rats.
Bakker, EN; Groma, G; Spijkers, LJ; de Vos, J; van Weert, A; van Veen, H; Everts, V; Arribas, SM; VanBavel, E
PloS one  9  e107998  2014

Show Abstract
ImmunohistochemistryRat25251068 25251068
Autologous minced muscle grafts: a tissue engineering therapy for the volumetric loss of skeletal muscle.
Corona, BT; Garg, K; Ward, CL; McDaniel, JS; Walters, TJ; Rathbone, CR
American journal of physiology. Cell physiology  305  C761-75  2013

Show Abstract
23885064 23885064
Cessation of epithelial Bmp signaling switches the differentiation of crown epithelia to the root lineage in a β-catenin-dependent manner.
Yang, Z; Hai, B; Qin, L; Ti, X; Shangguan, L; Zhao, Y; Wiggins, L; Liu, Y; Feng, JQ; Chang, JY; Wang, F; Liu, F
Molecular and cellular biology  33  4732-44  2013

Show Abstract
24081330 24081330
Intra-articular changes precede extra-articular changes in the biceps tendon after rotator cuff tears in a rat model.
Cathryn D Peltz,Jason E Hsu,Miltiadis H Zgonis,Nicholas A Trasolini,David L Glaser,Louis J Soslowsky
Journal of shoulder and elbow surgery / American Shoulder and Elbow Surgeons ... [et al.]  21  2012

Show Abstract
21816629 21816629
Induction of osteogenic differentiation of adipose derived stem cells by microstructured nitinol actuator-mediated mechanical stress.
Strauß, S; Dudziak, S; Hagemann, R; Barcikowski, S; Fliess, M; Israelowitz, M; Kracht, D; Kuhbier, JW; Radtke, C; Reimers, K; Vogt, PM
PloS one  7  e51264  2012

Show Abstract
ImmunocytochemistryHuman23236461 23236461
Structural and functional analysis of intra-articular interzone tissue in axolotl salamanders.
Cosden-Decker, RS; Bickett, MM; Lattermann, C; MacLeod, JN
Osteoarthritis and cartilage / OARS, Osteoarthritis Research Society  20  1347-56  2012

Show Abstract
Immunohistochemistry22800772 22800772
A standardized rat model of volumetric muscle loss injury for the development of tissue engineering therapies.
Wu, X; Corona, BT; Chen, X; Walters, TJ
BioResearch open access  1  280-90  2012

Show Abstract
23515319 23515319
Cell-derived matrix enhances osteogenic properties of hydroxyapatite.
Gregory Tour,Mikael Wendel,Ion Tcacencu
Tissue engineering. Part A  17  2011

Show Abstract
20695777 20695777
Matrix metalloproteinase-8 overexpression prevents proper tissue repair.
Patricia L Danielsen,Anders V Holst,Henrik R Maltesen,Maria R Bassi,Peter J Holst,Katja M Heinemeier,Jørgen Olsen,Carl C Danielsen,Steen S Poulsen,Lars N Jorgensen,Magnus S Agren
Surgery  150  2011

Show Abstract
21875735 21875735

Related Products & Applications

Related Products

Product Families

Categories

Life Science Research > Antibodies and Assays > Primary Antibodies